Friday, July 10, 2026

pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA

Iovance Biotherapeutics

Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S

825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
Status
Public
HQ
825 Industrial Rd, Suite 400, San Carlos, California 94070, US
Founded
2007
Employees
916
Programs
36
Drugs
26
Patents
94
Clinical program

KK-LC-1 TCR-T cells

Phase 1 · mab · Gastric Cancer

KK-LC-1 TCR-T cells for Gastric Cancer is a Phase 1 program (mab) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

Internal code 192004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Iovance Biotherapeutics B.V.
Phase
Phase 1
Modality
mab
Indication
Gastric Cancer
Status
active
Trials
1